Asset Details
Do you wish to reserve the book?
Adjuvant (chemo)radiotherapy for patients with head and neck cancer: can comorbidity risk scores predict outcome?
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Adjuvant (chemo)radiotherapy for patients with head and neck cancer: can comorbidity risk scores predict outcome?
Do you wish to request the book?
Adjuvant (chemo)radiotherapy for patients with head and neck cancer: can comorbidity risk scores predict outcome?
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Adjuvant (chemo)radiotherapy for patients with head and neck cancer: can comorbidity risk scores predict outcome?
2024
Overview
Purpose
This study compares the objective American Society of Anesthesiologists (ASA) and Adult Comorbidity Evaluation-27 (ACE-27) scores with the subjective Eastern Cooperative Oncology Group performance status (ECOG PS) for patient outcome prediction.
Methods
We retrospectively analyzed head and neck squamous cell carcinoma patients treated with adjuvant (chemo)radiotherapy at the LMU Munich from June 2008 to June 2015. The study focused on associations between patient outcomes; treatment failures; known risk factors (including human papillomavirus [HPV] status and tumor stage); and the comorbidity indices ECOG-PS, ASA score, and ACE-27. The Kaplan–Meier method and Cox proportional hazards model were used for survival analysis and identifying independent risk factors.
Results
A total of 302 patients were analyzed, 175 received concurrent chemotherapy. Median follow-up was 61.8 months, and median age at diagnosis was 61 years. The 3‑ and 5‑year overall survival (OS) and disease-free survival (DFS) rates were 70.5%/60.2% and 64.7%/57.6%, respectively. Both ACE-27 and ASA showed significant correlations with OS in univariate and multivariate analyses, while ECOG-PS was significant only in univariate analysis. ASA and ACE-27 scores were also significantly correlated with local and locoregional recurrence, but only HPV status and tumor stage were significant in multivariate models.
Conclusion
ACE-27 and ASA score effectively categorize patients’ risks in adjuvant radiotherapy for head and neck cancer, proving more predictive of overall survival than ECOG-PS. These results underscore the importance of objective comorbidity assessment and suggest further prospective studies.
Publisher
Springer Berlin Heidelberg,Springer Nature B.V
Subject
/ Aged
/ Cancer
/ Carcinoma, Squamous Cell - mortality
/ Carcinoma, Squamous Cell - pathology
/ Carcinoma, Squamous Cell - therapy
/ Female
/ Germany
/ Head and Neck Neoplasms - mortality
/ Head and Neck Neoplasms - therapy
/ Humans
/ Male
/ Medicine
/ Oncology
/ Original
/ Otorhinolaryngologic Neoplasms - mortality
/ Otorhinolaryngologic Neoplasms - pathology
/ Otorhinolaryngologic Neoplasms - radiotherapy
/ Otorhinolaryngologic Neoplasms - therapy
/ Patients
/ Survival
/ Tumors
